Reporting a Novel Disease Causing Variant in PGAP3 Associated With Hyperphosphatasia and Intellectual Disability: A

Arash Salmaninejad1,2,3, Mohammad Reza Seyedtaghia4, Ali Hosseini Bereshneh5

  • 1Center for Individualized Medicine, Mayo Clinic, Rochester, Minnesota, USA.

Abstract

Insights

A novel pathogenic variant in the PGAP3 gene was identified in a patient with hyperphosphatasia with impaired intellectual development syndrome (HPMRS). This discovery expands the known genetic causes of this rare disorder.

Area of Science:

  • Genetics
  • Biochemistry
  • Rare Diseases

Background:

  • Hyperphosphatasia with impaired intellectual development syndrome (HPMRS), or Mabry syndrome, is a rare autosomal recessive disorder.
  • It is characterized by elevated alkaline phosphatase (ALP) levels, cognitive impairment, and seizures, stemming from deficiencies in glycosylphosphatidylinositol (GPI) synthesis or anchoring.
  • Key affected pathways include GPI biosynthesis, GPI anchor transfer, fatty acid remodeling, and GPI-anchored protein transport.

Purpose of the Study:

  • To identify the genetic cause of HPMRS in an 11-year-old girl with hyperphosphatasia and intellectual disability.
  • To expand the understanding of the genetic and phenotypic spectrum of HPMRS.
  • To evaluate the utility of exome sequencing (ES) and ALP assays in diagnosing HPMRS.

Main Methods:

  • Exome sequencing (ES) was employed to diagnose the proband.
  • Sanger sequencing was used to confirm the identified variant.
  • A comprehensive literature review was performed to analyze the PGAP3 gene's role in HPMRS.

Main Results:

  • A novel homozygous pathogenic variant (c.202dupT, p.Cys68fs*2) in the PGAP3 gene was identified in the patient.
  • This variant segregated within the family and has not been previously reported in association with HPMRS.
  • The identified variant is predicted to disrupt PGAP3 protein function and potentially impair GPI biosynthesis.

Conclusions:

  • The p.Cys68fs*2 variant in PGAP3 is likely pathogenic and contributes to HPMRS.
  • This finding broadens the mutational spectrum of HPMRS.
  • Elevated ALP assays and ES are crucial diagnostic tools for identifying HPMRS and understanding its genetic basis.

Related Concept Videos

Genomic Imprinting and Inheritance02:30

Genomic Imprinting and Inheritance

Diploid organisms inherit genetic material through chromosomes from both parents. Copies of the same gene are known as alleles. In most cases, both alleles are simultaneously expressed and allow various cellular processes to function optimally. If one of the alleles is missing or mutated, the expression of the other allele can compensate; however, this is not true for all genes.
The expression of some genes depends on which parent passed the gene to the offspring, through a phenomenon known as...
38.6K
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
76
Inborn Errors of Metabolism01:20

Inborn Errors of Metabolism

Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
998